Inhibitor treatment: State of the art
- 1 January 2003
- journal article
- Published by Elsevier in Disease-a-Month
- Vol. 49 (1) , 22-38
- https://doi.org/10.1016/s0011-5029(03)90012-5
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Inhibitor Antibodies to Factor VIII and Factor IX: ManagementSeminars in Thrombosis and Hemostasis, 2000
- Continuous infusion of recombinant activated factor VII during caesarean section delivery in a patient with congenital factor VII deficiencyHaemophilia, 2000
- Recombinant FVIIa (NovoSeven) continuous infusion and total hip replacement in patients with haemophilia and high titre of inhibitors to FVIII: experience of two casesHaemophilia, 2000
- Continuous Infusion of Recombinant Factor VIIa in Hemophilic Patients with Inhibitors: Safety, Monitoring, and Cost EffectivenessSeminars in Thrombosis and Hemostasis, 2000
- The Continuous Infusion of Recombinant Activated Factor VIIa (rFVIIa) in Patients with Factor VIII Inhibitors Activates the Coagulation and Fibrinolytic Systems without Clinical ComplicationsThrombosis Research, 2000
- Experience with continuous infusion of recombinant activated factor VII in the Asia-Pacific regionBlood Coagulation & Fibrinolysis, 2000
- Treatment with recombinant activated factor VII in a patient with hemophilia A and an inhibitorBlood Coagulation & Fibrinolysis, 1999
- Recombinant factor VIIa in continuous infusion during central line insertion in a child with factor VIII high-titre inhibitorHaemophilia, 1998
- Safety, efficacy and lessons from continuous infusion with rFVIIaHaemophilia, 1998
- Pharmacokinetics and pharmacodynamics of recombinant factor VIIaClinical Pharmacology & Therapeutics, 1994